VEGF and depression: A comprehensive assessment of clinical data

Journal of Psychiatric Research

Volumn 47, Issue 8, 2013, Pages 1080-1087

  Clark Raymond, Anne ^a   Halaris, Angelos ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Depression; Neurogenesis; VEGF

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; MESSENGER RNA; OLANZAPINE; PAROXETINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIDEPRESSANT ACTIVITY; BODY MASS; DENTATE GYRUS; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN FUNCTION; PSYCHOPHARMACOTHERAPY; REVIEW; SIGNAL TRANSDUCTION;

EID: 84878652233     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.04.008     Document Type: Review

References (37)

1. Boldrini M., Hen R., Underwood M.D., Rosoklija G.B., Dwork A.J., Mann J.J., et al. Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Journal of Biological Psychiatry 2012, 72(7):562-571.
2. Cao L., Jiao X., Zuzga D.S., Liu Y., Fong D.M., Young D., et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nature Genetics 2004, 36(8):827-835.
3. Dome P., Telezi Z., Rihmer Z., Peter L., Dobos J., Kenessey I., et al. Circulating endothelial progenitor cells and depression: a possible link between heart and soul. Molecular Psychiatry 2009, 14:523-531.
4. Dome P., Halmai Z., Dobos J., Lazary J., Gonda X., Kenessey I., et al. Investigation of circulating endothelial progenitor cells and angiogenic and inflammatory cytokines during recovery from an episode of major depression. Journal of Affective Disorders 2012, 136:1159-1163.
5. Domenici E., Willé D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 2010, 5(2):e9166.
6. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biological Psychiatry 2006, 59:1116-1127.
7. Duric V., Duman R.S. Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell and Molecular Life Sciences 2013, 70(1):39-53. Epub 2012 May 15. http://dx.doi.org/10.1007/s00018-012-1020-7.
8. Eisch A.J., Barrot M., Schad C.A., Self D.W., Nestler E.J. Opiates inhibit neurogenesis in the adult rat hippocampus. Proceedings of the National Academy of Sciences 2000, 97(13):7579-7584.
9. Elfving B., Plougmann P.H., Wegener G. Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neuroscience Letters 2010, 474:13-16.
10. Emanuele E., Orsi P., Barale F., di Nemi S.U., Bertona M., Politi P. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism. Clinical Biochemistry 2010, 43(3):317-319.
11. Fulzele S. Pillai A. Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. Schizophrenia Research 2009, 115(2-3):372-373.
12. Hanson N.D., Owens M.J., Nemeroff C.B. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011, 36:2589-2602.
13. Heine V.M., Zareno J., Maslam S., Joëls M., Lucassen P.J. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. European Journal of Neuroscience 2005, 21(5):1304-1314.
14. Ibrahim L., Duncan W., Luckenbaugh D.A., Yuan P., Machado-Viera R., Zarate C.A. Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study. Brain Research Bulletin 2011, 86:129-133.
15. Iga J., Ueno S., Yamauchi K., Numata S., Tayoshi-Shibuya S., Kinouchi S., et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2006, 31:658-663.
16. Isung J., Mobarrez F., Nordström P., Asberg M., Jokinen J. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World Journal of Biological Psychiatry 2011, 13(6):468-473.
17. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., Greenberg D.A. Vascular endothelial growth factor stimulates neurogenesis in vitro and in vivo. Proceedings of the National Academy of Sciences 2002, 99(18):11946-11950.
18. Kahl K.G., Bens S., Ziegler K., Rudolf S., Kordon A., Dibbelt L., et al. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009, 34:353-357.
19. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biological Psychiatry 2004, 56(8):570-580.
20. Kotan Z., Sarandöl E., Kirhan E., Özkaya G., Kirli S. Serum Brain Derived Neurotrophic Factor (BDNF), Vascular endothelial growth factor (VEGF) and leptin levels in patients with the diagnosis of severe major depressive disorder with melancholic features. Therapeutic Advances in Psychopharmacology 2012, 2(2):65-74.
21. Lee B.H., Kim Y.K. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. Journal of Affective Disorders 2012, 136(1-2):181-184.
22. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935):1306-1309.
23. Madsen T.M., Treschow A., Bengzon J., Bolwig T.G., Lindvall O., Tingström A. Increased neurogenesis in a model of electroconvulsive therapy. Biological Psychiatry 2000, 47(12):1043-1049.
24. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience 2000, 20(24):9104-9110.
25. McCloskey D.P., Croll S.D., Scharfman H.E. Depression of synaptic transmission by Vascular Endothelial Growth Factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. The Journal of Neuroscience 2005, 25(39):8889-8897.
26. Minelli A., Zanardini R., Abate M., Bortolomasi M., Gennarelli M., Bocchio-Chiavetto L. Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry 2011, 35:1322-1325.
27. Nowacka M.M., Obuchowicz E. Vascular endothelial growth factor (VEGF) and its role in the central nervous system: A new element in the neurotrophic hypothesis of antidepressant drug action. Neuropeptides 2012, 46:1-10.
28. Palmer T.D., Willhoite A.R., Gage F.H. Vascular niche for adult hippocampal neurogenesis. The Journal of Comparative Neurology 2000, 425:479-494.
29. Schmid H.D., Shelton R.C., Duman R.S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011, 36:2375-2394.
30. Storkebaum E., Lambrechts D., Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004, 26(9):943-954.
31. Sun R., Li N., Li T. VEGF regulates antidepressant effects of lamotrigine. European Neuropsychopharmacology 2012, 22:424-430.
32. Takebyashi M., Hashimoto R., Hisaoka K., Tsuchioka M., Kunugi H. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. Journal of Neural Transmission 2010, 117:1119-1122.
33. Tsai S.J., Hong C.J., Lious Y.J., Chen T.J., Chen M.L., Hou S.J., et al. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Research 2009, 169(2):113-117.
34. Ventriglia M., Zanardini R., Pedrini L., Placentino A., Nielson M.G., Gennarelli M., et al. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009, 33:146-149.
35. Viikki M., Anttila S., Kampman O., Illi A., Huuhka M., Setälä-Soikkeli E., et al. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neuroscience Letters 2010, 477:105-108.
36. Warner-Schmidt J.L., Duman R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proceedings of the National Academy of Sciences 2007, 104(11):4647-4652.
37. Warner-Schmidt J.L., Duman R.S. VEGF as a potential target for therapeutic intervention in depression. Current Opinions in Pharmacology 2008, 8(1):14-19.